Comparing disease activity indices in ulcerative colitis.
暂无分享,去创建一个
G. Collins | S. Travis | D. Burger | A. Walsh | S. Keshav | A. Ghosh | A. Brain | O. Buchel | S. Thomas | L. White | A. J. Walsh | A. Ghosh | A. O. Brain | O. Buchel | D. Burger | S. Thomas | L. White | G. S. Collins | S. Keshav | S.P.L. Travis | Gary S. Collins
[1] D. Altman,et al. Translational Gastroenterology , 2011 .
[2] W. Tremaine,et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.
[3] G. Guyatt,et al. Assessing disease activity in ulcerative colitis: Patients or their physicians? , 2010, Inflammatory bowel diseases.
[4] Å. Danielsson,et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.
[5] M. Schwartz,et al. Is Endoscopy Necessary for the Measurement of Disease Activity in Ulcerative Colitis? , 2005, The American Journal of Gastroenterology.
[6] J. R. Landis,et al. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. , 1977, Biometrics.
[7] Ami,et al. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.
[8] J. H. Baron,et al. Variation Between Observers in Describing Mucosal Appearances in Proctocolitis* , 1964, British medical journal.
[9] S. Truelove,et al. Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.
[10] P. Rutgeerts,et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. , 2013, Gastroenterology.
[11] C. O'Morain,et al. Review article: defining remission in ulcerative colitis , 2011, Alimentary pharmacology & therapeutics.
[12] L. Sutherland,et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.
[13] J. Lennard-jones,et al. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. , 1978, Scandinavian journal of gastroenterology.
[14] D. Present,et al. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis , 1990, The Lancet.
[15] A. Öst,et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.
[16] M. Silverberg,et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] Philippe Marteau,et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.
[18] A. Cohen,et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.
[19] M. Schwartz,et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis , 2005, Gut.
[20] Paul Rutgeerts,et al. Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.
[21] T. Yao,et al. An index of disease activity in patients with ulcerative colitis. , 1992, The American journal of gastroenterology.
[22] P. Rutgeerts,et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. , 2003, Gastroenterology.
[23] J. Reguła,et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. , 2009, Gastroenterology.
[24] R. Pounder,et al. A simple clinical colitis activity index , 1998, Gut.
[25] S. Truelove,et al. Cortisone in Ulcerative Colitis , 1954 .
[26] D. Altman,et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. , 2013, Gastroenterology.
[27] S. Vermeire,et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. , 2012, Journal of Crohn's & colitis.
[28] J. Rochon,et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.
[29] J. Satsangi,et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.
[30] M. Welfare,et al. Defining Relapse of Ulcerative Colitis Using a Symptom-based Activity Index , 2003, Scandinavian journal of gastroenterology.